Core Viewpoint - Qingdao Haier Biomedical Co., Ltd. announced that its actual controller's concerted action party, Haichuangzhi, has completed a share buyback plan, acquiring 5,729,305 shares, which is 1.8% of the total share capital, for a total amount of 181.84 million yuan [2][8]. Group 1 - The share buyback plan was initiated on January 8, 2025, with a target to purchase between 100 million yuan and 200 million yuan within six months [2][6]. - As of April 10, 2025, Haichuangzhi has completed the buyback, with an average purchase price of 31.74 yuan per share [7][8]. - Following the buyback, Haichuangzhi holds 8,675,900 shares, representing 2.73% of the total share capital, while Haier Group and its concerted action parties collectively hold 141,371,022 shares, or 44.46% of the total [8]. Group 2 - The purpose of the buyback is to enhance investor confidence based on the belief in the company's future development and long-term investment value [4]. - The buyback was executed through a centralized bidding method on the Shanghai Stock Exchange [7]. - The buyback plan did not set a price range and was subject to market conditions [7].

证券代码：688139 证券简称：海尔生物 公告编号：2025-031 2025 年 4 月 10 日，公司收到实际控制人的一致行动人海创智《关于增持青 岛海尔生物医疗股份有限公司股份结果的通知》，现将有关情况公告如下： 1 一、增持主体的基本情况 （一）增持主体的名称：青岛海创智管理咨询企业（有限合伙） （二）本次增持前，海创智持有公司股份 2,946,595 股，占公司总股本的 0.93%，海尔集团公司通过其控制的青岛海尔生物医疗控股有限公司和青岛海创 睿股权投资基金中心（有限合伙）分别持有公司股份 100,591,463 股和 32,103,659 股，分别占公司总股本的 31.64%和 10.10%。海尔集团公司及其一致 行动人合计持有公司股份 135,641,717 股，占公司总股本的 42.66%。 青岛海尔生物医疗股份有限公司 关于实际控制人的一致行动人增持公司 股份结果的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 20 ...

二〇二五年四月 北京市中伦律师事务所 北京市中伦律师事务所 关于青岛海尔生物医疗股份有限公司 实际控制人之一致行动人增持公司股份的 专项核查意见 对于本核查意见，本所律师作出如下声明： 1. 本所律师在工作过程中，已得到海尔生物的保证：即公司业已向本所律 师提供了本所律师认为制作本核查意见所必需的原始书面材料、副本材料、扫描 件、复印件和口头证言，其所提供的文件和材料是真实、准确和完整的，且无隐 瞒、虚假和重大遗漏之处。 2. 本所律师依据本核查意见出具之日以前已经发生或者存在的事实和《公 司法》《证券法》等国家现行法律、法规、规范性文件和中国证券监督管理委员 会（以下简称"中国证监会"）的有关规定发表法律意见。 关于青岛海尔生物医疗股份有限公司 实际控制人之一致行动人增持公司股份的 专项核查意见 致：青岛海尔生物医疗股份有限公司 北京市中伦律师事务所接受委托就青岛海尔生物医疗股份有限公司（以下简 称"海尔生物"或"公司"）实际控制人海尔集团公司（以下简称"海尔集团"） 之一致行动人青岛海创智管理咨询企业（有限合伙）（以下简称"海创智"）增持 海尔生物股份（以下简称"本次增持"）的相关事宜出具《北京市中伦律师 ...

当前，AI与医疗健康的融合已从技术探索迈向规模化应用，推动行业进入数智化转型新阶段。4月8日-11日， 在 第91届中国国际医疗器械(春季)博览会 (以下简称"CMEF") 上，盈康一生旗下 海尔生物医疗 以"Ai在海 尔，因Ai盈康 "为主题，携多个"AI+智慧场景"和15大明星产品重磅亮相。 从AI+智慧样本库、AI+智慧科研，到AI+智慧用药、AI+智慧疫苗接种、AI+智慧血液管理，海尔生物医疗以新 科技、新场景、新生态，不仅为行业带来一场生命科学与医疗创新+AI的生态成果盛宴，也为产业重构带来了 未来想象空间。 # 逐"绿"向"智"，构建生命科学研究新范式 在可持续发展与智能化转型浪潮下，绿色科技与AI技术正重构生命科学产业范式，加速推进全链条数智化进 程。此次CMEF上，海尔生物医疗立足 样本高质量保藏管理和医院临床干细胞研究 ，为高校、科研机构、医 院、药企等用户带来了 一站式样本库全生命周期解决方案、可按需定制的智慧实验室场景解决方案 等，助力 生命科学研究和前沿医学进步。 在AI+智慧样本库展区，海尔生物医疗立足高质量样本库建设需求，带来了 一站式样本库全生命周期解决方案 和4大首发新品。 基 ...

Investment Rating - The report maintains a "Recommended" rating for Haier Biomedical (688139) with a target price of 42 yuan [2][8]. Core Views - The company reported a total revenue of 2.284 billion yuan for 2024, reflecting a slight increase of 0.13% year-on-year, while the net profit attributable to shareholders decreased by 9.71% to 367 million yuan [2][4]. - In Q4 2024, revenue accelerated to 502 million yuan, marking a growth of 10.40%, and net profit attributable to shareholders increased by 17.63% to 57 million yuan [2][4]. - The report highlights that the company is gradually returning to normal operations, with improving order growth despite challenges in the external environment [8]. Financial Summary - The projected total revenue for 2025 is estimated at 2.630 billion yuan, with a year-on-year growth rate of 15.2% [4]. - The net profit for 2025 is expected to reach 442 million yuan, representing a growth of 20.6% compared to 2024 [4]. - The company's gross margin for 2024 was reported at 47.99%, with an adjusted figure of 50.43% when accounting for changes in accounting policies [8]. Business Segment Performance - The Life Sciences segment achieved a revenue of 1.094 billion yuan in 2024, reflecting a growth of 6.14% [8]. - The Medical Innovation segment reported a revenue of 1.180 billion yuan, down 4.91% year-on-year, primarily due to disruptions from solar vaccine projects [8]. - Domestic revenue grew by 4.75% to 1.559 billion yuan, while overseas revenue decreased by 8.73% to 715 million yuan, although it showed signs of recovery in Q4 [8]. Future Outlook - The report anticipates that the net profit for 2025-2027 will be 440 million, 540 million, and 640 million yuan respectively, with corresponding growth rates of 20.6%, 23.1%, and 18.3% [8]. - The overall valuation of the company is estimated at 13.3 billion yuan, corresponding to the target price of approximately 42 yuan [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance is gradually stabilizing, and it is expected to return to a good growth trajectory in 2025 [1][5] - The life sciences segment is experiencing continuous innovation and growth, with new product categories accelerating [5] - The medical innovation segment is recovering, with strong growth in hospital automation and public health services [5] - The company has a clear advantage in its niche areas and is actively expanding new business lines, with new orders growing rapidly [5] Financial Summary - Revenue for 2022 was 2,864.04 million, with a year-on-year growth of 34.72%. In 2023, revenue decreased to 2,280.90 million, a decline of 20.36%. It is projected to increase to 2,594.89 million in 2025, reflecting a growth of 13.62% [2] - Net profit attributable to the parent company was 600.79 million in 2022, down 28.90% year-on-year. It is expected to recover to 408.08 million in 2025, with a growth of 11.31% [2] - The gross margin for 2024 is projected to be 47.99%, with a slight decline from previous years [2] - The company’s earnings per share (EPS) for 2025 is expected to be 1.28 yuan, with a price-to-earnings (PE) ratio of 24.95 [2][5] Segment Performance - The life sciences segment generated revenue of 1,094 million in 2024, a year-on-year increase of 6.14%, driven by new product launches [5] - The medical innovation segment's revenue was 1,180 million in 2024, a decrease of 4.91%, but showing signs of recovery in automation and digital services [5] Future Projections - The company is expected to achieve net profits of 4.08 million, 4.83 million, and 5.64 million for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.28, 1.52, and 1.77 yuan [5][6]

Group 1: Core Insights - The report discusses the impact of Trump's tariffs and countermeasures on various industries, highlighting the need for a trading mindset in consumer stocks [3] - It notes significant fluctuations in global asset prices due to trade uncertainties, with a focus on the quantitative monitoring of trade uncertainty and global panic trading levels [4] Group 2: Industry Performance - The shipping industry is directly affected by the tariffs, with a notable increase in container shipping volume from Asia to North America during the 2018 trade war, which saw a 6.63% year-on-year increase and a 175.77% rise in freight rates [5] - The report indicates that the shipping demand on the US route is exposed to high tariff risks, with no buffer period for the implementation of counter-tariffs, leading to a decline in export demand and potential impacts on shipping schedules and port efficiency [8] Group 3: Company Analysis - China Energy Construction (601868.SH) shows steady revenue growth with a significant expansion in new energy installations, projecting net profits of 9.3 billion, 10 billion, and 10.5 billion for 2025-2027, with respective growth rates of 10%, 8%, and 5% [10] - Haier Biomedical (688139.SH) reported a slight revenue increase of 0.13% in 2024, with a net profit of 367 million, although it experienced a decline of 9.71% year-on-year; however, the company is expected to see a recovery in 2025 with projected revenues of 2.623 billion, 3.023 billion, and 3.479 billion for 2025-2027, reflecting growth rates of 14.9%, 15.2%, and 15.1% respectively [11][12]

Investment Rating - The report maintains a "Buy" rating for Haier Biomedical [6] Core Views - The company's operational resilience is highlighted, with revenue showing a quarter-on-quarter improvement since the second half of 2024, while profit performance is impacted by changes in investment net income [2][3] - Non-storage new industries are experiencing robust growth, with a 21.25% year-on-year increase, and the company is embracing AI-driven digital transformation [3] - Domestic market advantages are being solidified, with a 4.75% year-on-year increase in domestic revenue, while overseas market disruptions have been largely mitigated [4] Financial Performance Summary - In 2024, Haier Biomedical achieved operating revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit attributable to shareholders decreased by 9.71% to 367 million yuan [1][5] - The company reported a gross margin of 47.99% in 2024, with a stable adjusted gross margin of 50.43% [2] - The investment net income for 2024 was 23.8 million yuan, down 71.34% year-on-year, affecting profit growth [2] Revenue and Profit Forecast - The forecast for operating revenue from 2025 to 2027 is 2.623 billion yuan, 3.023 billion yuan, and 3.479 billion yuan, representing year-on-year growth rates of 14.9%, 15.2%, and 15.1% respectively [4][5] - The projected net profit attributable to shareholders for the same period is 448 million yuan, 535 million yuan, and 649 million yuan, with growth rates of 22.1%, 19.5%, and 21.3% respectively [4][5]

Investment Rating - The report maintains a "Buy" rating for Haier Biomedical [6] Core Views - The company's operational resilience is highlighted, with revenue showing quarter-on-quarter improvement since the second half of 2024, while profit performance is impacted by changes in investment net income [2][3] - Non-storage new industries are experiencing robust growth, with a 21.25% year-on-year increase, and the company is embracing AI-driven digital transformation [3] - Domestic market advantages are being solidified, with a 4.75% year-on-year increase in domestic revenue, while overseas market disruptions have been largely mitigated [4] Financial Performance Summary - In 2024, Haier Biomedical achieved operating revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit attributable to shareholders decreased by 9.71% to 367 million yuan [1][5] - The company reported a gross margin of 47.99% in 2024, a decrease of 2.64 percentage points year-on-year, but adjusted gross margin remains stable at 50.43% [2] - The investment net income for 2024 was 23.8 million yuan, down 71.34% year-on-year, affecting profit growth [2] Revenue and Profit Forecast - Revenue projections for 2025-2027 are 2.623 billion, 3.023 billion, and 3.479 billion yuan, representing year-on-year growth rates of 14.9%, 15.2%, and 15.1% respectively [4][5] - Net profit forecasts for the same period are 448 million, 535 million, and 649 million yuan, with growth rates of 22.1%, 19.5%, and 21.3% respectively [4][5]

Group 1 - The core viewpoint of the news is that Haier Bio has made significant progress in mergers and acquisitions, AI empowerment, and R&D investment in 2024, with a 50% increase in revenue from the merger industry [1] - Haier Bio's AI empowerment spans five industries, including the integration of vaccine appointment systems with DeepSeek and the construction of various product solutions for smart medication scenarios [1] - The company focuses its R&D investment on traditional advantageous fields, emerging industry development, and future industry layout, with approximately one-third of new users in the domestic market coming from county-level markets and key core user groups [1] Group 2 - The international market strategy involves a "one country, one policy" approach to enhance localization capabilities, emphasizing regional product planning and expanding new user scenarios [1] - Non-storage business is experiencing rapid growth overseas, with expectations for continued positive development [1] - Domestic orders are abundant, and overseas orders are rolling, with a business opportunity funnel exceeding 10 billion [1]